OD 00910
Alternative Names: OD-00910Latest Information Update: 20 Feb 2025
At a glance
- Originator Odyssey Therapeutics
- Class Antibodies; Antihyperglycaemics; Skin disorder therapies
- Mechanism of Action Tumour necrosis factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus; Type 1 diabetes mellitus; Vitiligo
Most Recent Events
- 20 Feb 2025 Preclinical trials in Systemic lupus erythematosus in USA (Parenteral) (Odyssey Therapeutics pipeline, February 2025)
- 20 Feb 2025 Preclinical trials in Type 1 diabetes mellitus in USA (Parenteral) (Odyssey Therapeutics pipeline, February 2025)
- 20 Feb 2025 Preclinical trials in Vitiligo in USA (Parenteral), prior to February 2025 (Odyssey Therapeutics pipeline, February 2025)